



PolyNovo Limited
ABN 96 083 866 862

2/320 Lorimer Street
Port Melbourne
VIC Australia 3207

P +61 (0) 3 8681 4050
F +61 (0) 3 8681 4099

26 October 2022

ASX Announcement

Hong Kong –Two cases, Two Surgeons

PolyNovo reports the treatment of two patients in Hong Kong using NovoSorb BTM.

Hong Kong is evidence of the Boards stated intention to lift the priority of pursuing India, China, Japan, and other jurisdictions.

Earlier this month, the Company sent our senior Australian saleswoman to Hong Kong for a week to scope and seed the market. The interest and take-up of BTM were immediate and exciting.

- The first patient was a reconstruction case treated with NovoSorb BTM.
- The second patient had a 33% partial / full thickness burn and the full thickness area was treated with NovoSorb BTM.
- The procedures were conducted by two different surgeons from the same Centre of Excellence Hospital
- Additional surgeons in the same and other hospitals have also expressed interest in using the product
- The Company intends to send staff back to Hong Kong in circa a month to reinforce our market entry and to determine what ongoing resources are needed on the ground

Chairman, David Williams said *“Hong Kong is an exciting market for PolyNovo, and also provides access to patients from the Greater Bay Area. We also see this as a window for patients from the mainland while waiting regulatory approval in China. We are following the lead of companies like China Grand who purchased Sirtex and are treating mainland patients in Hong Kong.”*

Chief Executive Officer, Swami Raote said *“We are very pleased with our sales team’s initiative and the support of the head office team in completing the first two cases in Hong Kong. The first two cases being a mix of indications, one burn and the other reconstruction, demonstrates the versatility of BTM and the market opportunity.”*

This announcement has been authorised by PolyNovo Company Secretary Jan-Marcel Gielen.

About PolyNovo®

PolyNovo is a disruptive medical device company, focused on Advanced Wound Care. PolyNovo is an Australian based medical device company that designs, develops, and manufactures dermal regeneration solutions (NovoSorb BTM) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information and market presentations see www.polynovo.com

About NovoSorb®

NovoSorb® BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery or burn. NovoSorb® is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.